<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577459</url>
  </required_header>
  <id_info>
    <org_study_id>1986-033</org_study_id>
    <secondary_id>TR701-114</secondary_id>
    <nct_id>NCT01577459</nct_id>
  </id_info>
  <brief_title>A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response</brief_title>
  <official_title>A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response to Pseudoephedrine Concurrent With Placebo or TR 701 FA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the
      pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized to 1 of 2 possible treatment sequences (N=9 per
      sequence) on Study Day 1. Subjects will receive oral 200 mg TR 701 FA or Placebo for TR 701
      FA once daily for 5 days during each treatment period, with a 2 day washout between periods
      (72 hours between doses). On Study Day 5 of each treatment period, subjects will also receive
      oral 60 mg PSE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2012</start_date>
  <completion_date type="Actual">June 15, 2012</completion_date>
  <primary_completion_date type="Actual">June 15, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>13 days</time_frame>
    <description>To compare systolic blood pressure post administration of pseudoepherine concurrent with TR-701 FA and Placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TR-701 FA with PSE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR-701 FA 200 mg oral with PSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TR-701 FA Placebo with PSE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TR-701 FA Placebo 200 mg oral with PSE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA with PSE</intervention_name>
    <description>TR-701 FA Oral 200 mg oral with PSE</description>
    <arm_group_label>TR-701 FA with PSE</arm_group_label>
    <other_name>Tedizolid Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TR-701 FA Placebo with PSE</intervention_name>
    <description>TR-701 FA Placebo Oral 200 mg with PSE</description>
    <arm_group_label>TR-701 FA Placebo with PSE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18 and 45 years of age, inclusive

          -  Healthy males and females with no clinically significant abnormalities identified by a
             detailed medical history

          -  Body mass index ≥ 19.0 kg/m2 and ≤ 31.0 kg/m2

        Exclusion Criteria:

          -  Systolic blood pressure &gt; 130 mmHg or &lt; 90 mmHg measured after 10 minutes supine at
             the Screening Visit and Study Day 1

          -  Diastolic blood pressure &gt; 90 mmHg or &lt; 60 mmHg measured after 10 minutes supine at
             the Screening Visit and Study Day 1

          -  Heart rate &gt; 90 bpm or &lt; 50 bpm measured after 10 minutes supine at the Screening
             Visit and Study Day

          -  Known allergy or hypersensitivity to PSE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe G Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator Site 001</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

